News
Interview: GlycanAge launch first hospital-based tests
Biological age testing pioneer GlycanAge plans to use the cash raised from its recent US$8.7m funding round to expand its reach, explore additional bio-marking capabilities of its unique technology and fund its recently-opened Californian lab. Agetech World editor Peter McCusker met Jonathan White, head of its UK office, to find out more.
GlycanAge was founded in 2020 by Prof Gordan Lauc and his daughter Nikolina Lauc to capitalise on the former’s groundbreaking work on the capabilities of glycan sugars as ageing biomarkers.
Glycans coat all cell surfaces and are present in most human tissues where they help regulate cell signalling and development.
In his Zagreb lab Prof Lauc was able to interpret glycan signals around chronic inflammation as a pernicious – but reversible – drivers of premature ageing.
This led to the development of GlycanAge’s ‘inflammaging’ clock which estimates biological age by measuring patterns of glycan abundance on Immunoglobulin G’ – the most abundant antibody in blood.
This analysis allows for a detailed assessment of an individual’s biological age, and offers insights into how variable lifestyle choices – poor diet, stress, inactivity – and other environmental factors impact ageing.
World-leading US lab
Speaking to Agetech World from its headquarters on the Newcastle University-partnered Helix innovation hub, next to Newcastle United’s St James Park home, UK office head Jonathan White elaborated on its future ambitions and recounted its success to date.
“Glycan testing is a very complex process and about 85% of the underlying research on glycans and biological ageing stems from over 20 years of work by Prof Lauc and his team in their Zagreb lab.
Prof Gordan Lauc, co-founder, GlycanAge
“This latest investment round will allow us to produce indication-specific products – all from the original science – that can be implemented into various avenues such as a menopause-specific product, or a cardiovascular one, for example.
“We’ve recently established our second lab in California, which will streamline analysis and processing for our US clients and help us maintain our world-leading capabilities.”
GlycanAge’s unique chronic inflammation test involves analysis of a blood sample with the company having undertaken over 300,000 of these, worldwide, since inception.
Global potential
One area of interest to the GlycanAge team is in the onset of female menopause with Mr White highlighting how glycan testing can help smooth this process.
“This is a time of life when women are prime candidates for a chronic inflammatory-based disease to develop and in this environment there is the potential for our testing capabilities to be able to recognise this change and help with identifying approbate treatment, such as hormone supplements.”
Its geographical footprint is expanding rapidly with representation in the United Arab Emirates, South America, Singapore, New York, Japan, Indonesia, Bulgaria, and Spain..
As well as the recently-opened US lab it is on course to create an additional lab in the King Abdulaziz City for Science and Technology, in Saudi Arabia.
GlycanAge’s tests have mostly been adopted in private and individual health settings with the company now delivering its first lab-developed tests in a hospital setting.
Hospital setting
This year it expects to deploy its technology into more than 10 hospitals across Europe and the Middle East, with St Catherine Specialty Hospital in Zagreb recently becoming the first hospital globally to integrate glycan-based biomarkers into routine cardio-metabolic risk screening.
Professor Lauc said: “Hospitals are conservative – and they should be. But we’ve now made the first big step. We’ve put our machine into a hospital, and together with clinicians we’re developing diagnostic applications that actually make sense in practice.”
This is a key development for GlycanAge as it looks to see its technologies adopted in mainstream medical settings such as the UK National Health Service.
Although the company is realistic in recognising many existing healthcare systems are limited as they focus on symptoms, whilst the GlycanAge test focuses on measuring and tackling chronic inflammation, years before it manifests as a disease.
Last month, GlycanAge secured Its €7.4m (US$8.7m) in fresh funding following an earlier seed round In 2024, which saw the company raise €3.9m in seed-funding.
Its investors include Fifth Quarter Ventures, Guinness Ventures, BrightCap Ventures, South Central Ventures, Impetus Capital, Vesna Deep Tech VC, Lightfield Equity, LaunchHub Ventures and Kadmos Capital.
Gut-friendly foods such as kimchi and kombucha may carry hidden risks for heart health when eaten in excess, the British Heart Foundation (BHF) has warned.
The charity said foods marketed as prebiotic, probiotic or otherwise good for the gut can support the microbiome, but some may also be high in salt or sugar, which can raise the risk of cardiovascular disease.
Products highlighted by the British Heart Foundation included kimchi, kombucha, fruit yoghurts, smoothies and sauerkraut. It said there is no harm in including them as part of a healthy diet, but advised people to check labels for added salt and sugar and eat them in moderation.
Tracy Parker, the charity’s nutrition lead, said: “We encourage everyone to choose foods that can keep their gut microbiome healthy. The benefits are clear, and we are continuing to improve our understanding of how a gut-friendly diet may help our hearts.
“A lot of these products can contain high levels of salt or sugar though, so it is important to be aware of the potential drawbacks.
“By ensuring you check package labels for added salt and sugars, and eat each in moderation, you can make sure the risks do not outweigh the benefits for your heart health.”
Fermented foods such as kimchi and sauerkraut are rich in probiotics, the healthy bacteria produced during fermentation that can help support a diverse and healthy gut microbiome.
However, both are traditionally made using a lot of salt, which can raise blood pressure if eaten frequently or in large quantities. High blood pressure is known to increase the risk of heart attack and stroke.
Kombucha, a fermented tea, also contains probiotics and can be a healthier alternative to fizzy drinks, but many commercial and shop-bought versions contain added sugar.
Eating too much sugar can lead to weight gain, which can increase the risk of heart attack, stroke and other cardiovascular disease.
Fruit yoghurts can contain probiotic live bacteria cultures, but may also be high in sugar and have fewer live cultures than plain versions.
The charity said plain yoghurt with live and active cultures on the label can be a lower-sugar option, with whole fruit added at home for sweetness.
Smoothies made with whole fruits provide prebiotic fibre, which feeds beneficial gut bacteria and supports digestive health.
They can also provide vitamins and antioxidants, especially when made with a variety of plant-based ingredients.
But blending breaks down the structure of fruit, releasing free sugars that behave like added sugars in the body and can cause faster rises in blood sugar levels.
Regularly consuming too much sugar can lead to weight gain, which can increase the risk of developing type 2 diabetes, heart disease and kidney disease.
The charity said only one 150ml serving of any smoothie counts towards five-a-day, and suggested adding nuts or seeds for extra protein and fibre to help keep blood sugar levels more stable.
The BHF also noted that some shop-bought sauerkraut is pasteurised, which removes most of the live bacteria.
It advised checking the label, eating small portions and choosing unpasteurised products for those seeking the probiotic benefits.
The charity said beneficial gut bacteria produce short-chain fatty acids during digestion, which are linked to reduced inflammation, better metabolism and better heart and circulatory health.
These good bacteria also help digest polyphenols, natural plant chemicals thought to have antioxidant properties and which may help lower blood pressure.
By contrast, harmful gut bacteria, which thrive on diets high in fat and red meat, produce chemicals that can cause problems in the heart and blood vessels by increasing inflammation and altering how cholesterol is processed in the body.
Beneficial bacteria thrive on varied diets high in prebiotics, non-digestible fibres found in foods such as wholegrains, oats, beans, lentils, bananas and onions.
People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.
Gut-friendly foods may damage heart, charity warns
Diabetes patients face increased risk of undiagnosed heart failure
UK government announces £6.3m fund to boost men’s health
Brain health collaboratory launches in Gulf South
Centenarian study probes healthy ageing
Centenarian study probes healthy ageing
Active sitting linked to lower dementia risk
Endogenex raises US$50m for diabetes procedure
Working nights undermines type 2 diabetes management – study
UK government announces £6.3m fund to boost men’s health
News4 weeks agoCentenarian study probes healthy ageing
- News4 weeks ago
Active sitting linked to lower dementia risk
- News4 weeks ago
Endogenex raises US$50m for diabetes procedure
- News4 weeks ago
Working nights undermines type 2 diabetes management – study
- Wellness4 weeks ago
UK government announces £6.3m fund to boost men’s health
- News4 weeks ago
Brain health collaboratory launches in Gulf South
- Wellness4 weeks ago
Social isolation is a horrible consequence of dementia – AI could be an answer
- News3 weeks ago
Diabetes patients face increased risk of undiagnosed heart failure
